Table 2 The relationship between NPS and clinical characteristics in NSCLC patients.
From: The prognostic value of the Naples prognostic score for patients with non-small-cell lung cancer
Variable | Category | Total (n = 395) | NPS | P value | ||
|---|---|---|---|---|---|---|
Group 0 (n = 46) | Group 1 (n = 236) | Group 2 (n = 113) | ||||
Age (years) | < 65 | 205 (51.9) | 32 (69.6) | 118 (50.0) | 55 (48.7) | 0.038 |
≥ 65 | 190 (48.1) | 14 (30.4) | 118 (50.0) | 58 (51.3) | ||
Gender | Male | 252 (63.8) | 23 (50.0) | 147 (62.3) | 82 (72.6) | 0.020 |
Female | 143 (36.2) | 23 (50.0) | 89 (37.7) | 31 (27.4) | ||
Smoking | Never | 200 (50.6) | 26 (56.5) | 124 (52.5) | 50 (44.2) | 0.243 |
Former/current | 195 (49.4) | 20 (43.5) | 112 (47.5) | 63 (55.8) | ||
Drinking | Yes | 84 (21.3) | 11 (23.9) | 52 (22.0) | 21 (18.6) | 0.684 |
No | 311 (78.7) | 35 (76.1) | 184 (78.0) | 92 (81.4) | ||
COPD | Yes | 17 (4.3) | 2 (4.3) | 12 (5.1) | 3 (2.7) | 0.578 |
No | 378 (95.7) | 44 (95.7) | 224 (94.9) | 110 (97.3) | ||
Family history of cancer | Yes | 62 (15.7) | 7 (15.2) | 37 (15.7) | 18 (15.9) | 0.994 |
No | 333 (84.3) | 39 (84.8) | 199 (84.3) | 95 (84.1) | ||
BMI (kg/m2) | < 18.5 | 34 (8.6) | 6 (13.0) | 15 (6.4) | 13 (11.5) | 0.098 |
18.5–24 | 257 (65.1) | 24 (52.2) | 156 (66.1) | 77 (68.1) | ||
≥ 24 | 104 (26.3) | 16 (34.8) | 65 (27.5) | 23 (20.4) | ||
TNM stage | I-IIIA | 138 (34.9) | 22 (47.8) | 88 (37.3) | 28 (24.8) | 0.011 |
IIIB-IV | 257 (65.1) | 24 (52.2) | 148 (62.7) | 85 (75.2) | ||
Histology | AC | 280 (70.9) | 35 (76.1) | 167 (70.8) | 78 (69.1) | 0.667 |
SCC | 99 (25.1) | 8 (17.4) | 60 (25.4) | 31 (27.4) | ||
Others | 16 (4.1) | 3 (6.5) | 9 (3.8) | 4 (3.5) | ||
Lesion | Central | 137 (34.7) | 14 (30.4) | 81 (34.3) | 42 (37.2) | 0.709 |
Peripheral | 258 (65.3) | 32 (69.6) | 155 (65.7) | 71 (62.8) | ||
Laterality | Left | 171 (43.3) | 15 (32.6) | 113 (47.9) | 43 (38.1) | 0.066 |
Right | 224 (56.7) | 31 (67.4) | 123 (52.1) | 70 (61.9) | ||
Surgery | Yes | 199 (50.4) | 28 (60.9) | 125 (53.0) | 46 (40.7) | 0.032 |
No | 196 (49.6) | 18 (39.1) | 111 (47.0) | 67 (59.3) | ||
Chemotherapy | Yes | 329 (83.3) | 38 (82.6) | 195 (82.6) | 96 (85.0) | 0.854 |
No | 66 (16.7) | 8 (17.4) | 41 (17.4) | 17 (15.0) | ||
Radiotherapy | Yes | 68 (17.2) | 5 (10.9) | 42 (17.8) | 21 (18.6) | 0.471 |
No | 327 (82.8) | 41 (89.1) | 194 (82.2) | 92 (81.4) | ||
Targeted therapy | Yes | 111 (28.1) | 12 (26.1) | 68 (28.8) | 31 (27.4) | 0.916 |
No | 284 (71.9) | 34 (73.9) | 168 (71.2) | 82 (72.6) | ||
CEA | < 6.5 ng/mL | 244 (61.8) | 30 (65.2) | 150 (63.6) | 64 (56.6) | 0.404 |
≥ 6.5 ng/mL | 151 (38.2) | 16 (34.8) | 86 (36.4) | 49 (43.4) | ||
NSE | < 17 ng/mL | 312 (79.0) | 38 (82.6) | 189 (80.1) | 85 (75.2) | 0.472 |
≥ 17 ng/mL | 83 (21.0) | 8 (17.4) | 47 (19.9) | 28 (24.8) | ||
Albumin | < 40 g/L | 136 (34.4) | 10 (21.7) | 58 (24.6) | 68 (60.2) | < 0.001 |
≥ 40 g/L | 259 (65.6) | 36 (78.3) | 178 (75.4) | 45 (39.8) | ||
Total cholesterol | ≤ 180 mg/dL | 205 (51.9) | 0 (0) | 97 (41.1) | 108 (95.6) | < 0.001 |
> 180 mg/dL | 190 (48.1) | 46 (100.0) | 139 (58.9) | 5 (4.4) | ||
NLR | ≤ 2.96 | 216 (54.7) | 46 (100.0) | 167 (70.8) | 3 (2.7) | < 0.001 |
> 2.96 | 179 (45.3) | 0 (0) | 69 (29.2) | 110 (97.3) | ||
LMR | ≤ 4.44 | 299 (75.7) | 0 (0) | 188 (79.7) | 111 (98.2) | < 0.001 |
> 4.44 | 96 (24.3) | 46 (100.0) | 48 (20.3) | 2 (1.8) | ||
PNI | < 46 | 116 (29.4) | 2 (4.3) | 42 (17.8) | 72 (63.7) | < 0.001 |
≥ 46 | 279 (70.6) | 44 (95.7) | 194 (82.2) | 41 (36.3) | ||
CONUT | < 3 | 288 (72.9) | 46 (100.0) | 208 (88.1) | 34 (30.1) | < 0.001 |
≥ 3 | 107 (27.1) | 0 (0) | 28 (11.9) | 79 (69.9) | ||
SIS | 0 | 77 (19.5) | 36 (78.3) | 41 (17.4) | 0 (0) | < 0.001 |
1 | 201 (50.9) | 10 (21.7) | 144 (61.0) | 47 (41.6) | ||
2 | 117 (29.6) | 0 (0) | 51 (21.6) | 66 (58.4) | ||
